Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study
Key Points
Surgical outcomes improved for patients receiving combination therapy with spartalizumab and FLOT.
The primary outcome measure, overall survival rate after 12 months, was notably higher in treated patients than in control groups.
Observational analysis combines treatments with fluorouracil, leucovorin, oxaliplatin, and docetaxel.
Demonstrates a promising approach using targeted therapy in a specific cancer type, emphasizing need for larger trials.
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study | Synapse